New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - ceftazidime pentahydrate 582.4mg equivalent to 500 mg ceftazidime - powder for injection - 500 mg - active: ceftazidime pentahydrate 582.4mg equivalent to 500 mg ceftazidime excipient: nitrogen sodium carbonate - ceftazidime sandoz is indicated for the treatment of single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. indications include: severe infections e.g. septicaemia, bacteraemia, peritonitis, meningitis; infections in immunosuppressed patients; infections in patients in intensive care, e.g. infected burns; respiratory tract infections including lung infections in cystic fibrosis; ear, nose and throat infections; urinary tract infections; skin and soft tissue infections; gastrointestinal, biliary and abdominal infections; bone and joint infections; infections associated with haemo-and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ceftazidime pentahydrate, quantity: 1164.8 mg (equivalent: ceftazidime, qty 1000 mg) - injection, powder for - excipient ingredients: sodium carbonate - treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime; as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antipseudomonal antibiotics cannot be used. indications include the folowing: severe infections in general (e.g. septicaemia including neonatal sepsis, bacteraemia; in patients in intensive care units with specific problems, e.g. infected burns). respiratory tract (e.g. pneumonia, bronchopneumonia, infected pleurisy, infected bronchiectasis and bronchitis). severe ear, nose and throat infections (e.g. otitis media, mastoiditis). urinary tract (e.g. acute and chronic pyelonephritis, pyelitis, cystitis - bacterial only; infections associated with bladder and renal stones). skin and soft tissue (e.g. erysipelas abscesses, cellulitis, infected burns and wounds, mastitis). gastrointestinal and abdominal (e.g. intra-abdominal abscesses, enterocolitis). bone and joint (e.g. osteitis, osteomyelitis, septic arthritis, infected burstis).

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ceftazidime pentahydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ceftazidime pentahydrate -

Malta - English - Medicines Authority

hospira uk limited horizon, honey lane, hurley, maidenhead sl6 6rj, united kingdom - ceftazidime pentahydrate - powder for solution for infusion or injection - ceftazidime pentahydrate 1.165 g - antibacterials for systemic use

Malta - English - Medicines Authority

hospira uk limited horizon, honey lane, hurley, maidenhead sl6 6rj, united kingdom - ceftazidime pentahydrate - powder for solution for injection/infusion - ceftazidime pentahydrate 2.330 g - antibacterials for systemic use

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - ceftazidime pentahydrate, quantity: 1175 mg (equivalent: ceftazidime, qty 1000 mg) - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime for injection is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. ,indications include the following:,severe infections in general: ,for example: septicaemia including neonatal sepsis, bacteraemia; and in patients in intensive care units with specific problems, e.g., infected burns.,respiratory tract infections: ,for example: pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis.,severe ear, nose and throat infections: ,for example: otitis media, mastoiditis.,urinary tract infections: ,for example: acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones.,skin and soft tissue infections: ,for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis.,gastrointestinal and abdominal infections: ,for example: intra-abdominal abscesses, enterocolitis.,bone and joint infections: ,for example: osteitis, osteomyelitis, septic arthritis, infected bursitis.

Malta - English - Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - ceftazidime pentahydrate - powder for solution for injection - ceftazidime pentahydrate 500 milligram(s) - antibacterials for systemic use

Malta - English - Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - ceftazidime pentahydrate - solution for injection/infusion - ceftazidime pentahydrate 1 gram(s) - antibacterials for systemic use

Malta - English - Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - ceftazidime pentahydrate - powder for solution for injection/infusion - ceftazidime pentahydrate 2 gram(s) - antibacterials for systemic use